Clinical Trials

Precision drug development*

 

Endocyte is currently sponsoring a clinical trial related to an oncology product candidate.

 

177Lu-PSMA-617

Phase 3 study is planned to enroll in the first half of 2018 (pending FDA regulatory interactions)

EC1169 PSMA Tubulysin (Closed for enrollment)

Phase 1 study of a targeting-tubulysin conjugate in patients with Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)

Medical professionals requesting additional information may contact clinical@endocyte.com

  1. * The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.